HUTCHMED China Ltd, formerly Hutchison China Meditech Ltd, is an investment holding company principally engaged in the manufacturing and sale of drugs.
Company profile
Ticker
HCM, HMDCF
Exchange
Website
CEO
Christian Hogg
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Hutchison China MediTech Ltd
SEC CIK
HCM stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
8 Apr 24
6-K
HUTCHMED Highlights Data to be Presented at AACR Congress 2024
5 Apr 24
6-K
Current report (foreign)
2 Apr 24
6-K
Current report (foreign)
28 Mar 24
6-K
HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
22 Mar 24
6-K
Grant of Share Options under Share Option Scheme and Awards under Long Term Incentive Plan
14 Mar 24
6-K
Vesting of awards under the Long Term Incentive Plan
5 Mar 24
6-K
HUTCHMED Reports 2023 Full Year Results and Provides Business Updates
28 Feb 24
20-F
2023 FY
Annual report (foreign)
28 Feb 24
6-K
HUTCHMED Highlights Presentation of Phase III Data on Fruquintinib in Second-Line Gastric Cancer at ASCO Plenary Series Session
7 Feb 24
Latest ownership filings
SC 13G/A
Capital International Investors
13 Feb 23
SC 13G/A
Capital International Investors
11 Feb 22
SC 13D/A
Epizyme, Inc.
7 Feb 22
SC 13D
Epizyme, Inc.
16 Aug 21
SC 13D/A
GENERAL ATLANTIC LLC
1 Jul 21
SC 13D/A
CK Hutchison Holdings Ltd
30 Jun 21
SC 13D/A
CK Hutchison Holdings Ltd
13 Apr 21
SC 13G/A
Capital International Investors
16 Feb 21
SC 13D/A
CK Hutchison Holdings Ltd
27 Nov 20
SC 13D/A
CK Hutchison Holdings Ltd
7 Jul 20
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 64 |
Opened positions | 9 |
Closed positions | 14 |
Increased positions | 14 |
Reduced positions | 22 |
13F shares | Current |
---|---|
Total value | 382.92 bn |
Total shares | 355.42 mm |
Total puts | 1.50 k |
Total calls | 4.90 k |
Total put/call ratio | 0.3 |
Largest owners | Shares | Value |
---|---|---|
CK Hutchison | 332.50 mm | $0.00 |
M&G Investment Management | 7.08 mm | $120.44 bn |
Schroder Investment Management | 4.22 mm | $71.47 bn |
General Atlantic | 4.00 mm | $67.76 bn |
BLVGF Bellevue | 1.80 mm | $30.58 bn |
Allianz Asset Management GmbH | 1.64 mm | $27.87 bn |
Millennium Management | 934.87 k | $15.84 bn |
Jane Street | 478.12 k | $8.10 bn |
GS Goldman Sachs | 412.61 k | $6.99 bn |
STT State Street | 392.96 k | $6.66 bn |
News
HUTCHMED Says Initial Preclinical Data For HMPL-506 Novel, Highly Potent And Differentiated Menin-MLL Inhibitor For The Treatment Of Certain Types Of Acute Leukemia At AACR Congress 2024
5 Apr 24
HUTCHMED And Innovent Announce NDA Acceptance In China For Fruquintinib Combination With Sintilimab For The Treatment Of Advanced Endometrial Cancer With Priority Review Status
2 Apr 24
On Wednesday, HUTCHMED Announced Savolitinib sNDA Accepted in China For Treatment-Naïve Or Previously Treated Patients With Locally Advanced Or Metastatic MET Exon 14 NSCLC
28 Mar 24
Hello Group Posts Q4 Results, Joins SentinelOne, Futu Holdings And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
14 Mar 24
Why Clover Health Investments Shares Are Trading Higher By 11%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
13 Mar 24
Press releases
HUTCHMED Highlights Data to be Presented at AACR Congress 2024
5 Apr 24
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Endometrial Cancer with Priority Review Status
2 Apr 24
HUTCHMED Announces Savolitinib sNDA Accepted in China for Treatment-Naïve or Previously Treated Patients with Locally Advanced or Metastatic MET Exon 14 NSCLC
27 Mar 24
HUTCHMED Initiates Registration Stage of the ESLIM-02 Phase II/III Trial of Sovleplenib for Warm Antibody Autoimmune Hemolytic Anemia in China
21 Mar 24
HUTCHMED Reports 2023 Full Year Results and Provides Business Updates
28 Feb 24